Press Release Forum [pressreleaseforum.com] Forum Index

Press Release Forum [pressreleaseforum.com]
Free Press Release Distribution

A site of EPR Network

 FAQFAQ   SearchSearch   MemberlistMemberlist   UsergroupsUsergroups   RegisterRegister 
 ProfileProfile   Log in to check your private messagesLog in to check your private messages   Log inLog in 

Real Time Press Release Distribution is here. Try it out, it's free!

 

AnaSpec Introduces Industry’s First Suite of MOG Reagents &a

 
Post new topic   Reply to topic    Press Release Forum [pressreleaseforum.com] Forum Index -> Biotech Press Releases
View previous topic :: View next topic  
Author Message
anaspec



Joined: 15 Aug 2006
Posts: 238
Location: 34801 Campus Drive, Fremont, CA 94555

PostPosted: Fri Jul 24, 2009 12:56 pm    Post subject: AnaSpec Introduces Industry’s First Suite of MOG Reagents &a Reply with quote

San Jose, CA – July 24, 2009

Myelin Oligodendrocyte Glycoprotein (MOG), a 26- to 28-kDa protein, is a member of the immunoglobulin superfamily. It is expressed exclusively in the central nervous system (CNS), specifically on the surface of myelinating oligodendrocytes and external lamellae of myelin sheath. Although MOG protein constitutes only 0.01-0.05% of the CNS myelin proteins, it was demonstrated that MOG protein is a crucial autoantigen for multiple sclerosis in humans and experimental autoimmune encephalomyelitis (EAE) in rodents and monkeys (1-6).

AnaSpec is pleased to be the first in the industry to provide a whole suite of reagents and assay kits for the advancement of MS research. This includes MOG proteins, peptides, antibodies and assay kits.

MOG Proteins
These proteins, with sequences corresponding to human, mouse and rat extracellular domain, together with a 6x His tag were expressed in E. coli and purified from urea denatured bacterial lysate. The molecular weight found in all 3 recombinant proteins was 14.23 kDa. These proteins were shown to induce EAE in either mouse (for the human and mouse rMOGs) or rat (for rat rMOG).


MOG (35-55) and other MOG Peptide Fragments
AnaSpec’s MOG (35-55) peptide from mouse and rat sequence (cat# 60130) was shown to induce anti-MOG (35-55) autoantibody production in C57BL/6 mice at 100% incidence (10/10); providing quantitative data that this peptide is suitable for in vivo anti-MOG (35-55) autoantibody study. A cysteine-containing MOG (35-55) peptide induced polyclonal anti-MOG (35-55) antibody production in rabbits with high specificity, high affinity, and high titer indicating its high purity, as well as suitability for use in peptide-coated ELISA and Western blot. This mouse/rat MOG (35-55) peptide was used as a coating peptide to develop the industry’s first anti-MOG (35-55) ELISA kit for EAE study. The detection limit of the kit was determined to reach as low as 50 pg of anti-MOG (35-55) autoantibody in serum or cerebrospinal fluid. Lot to lot variability of the MOG (35-55) was found to be minimal.


MOG Antibodies
Two rabbit polyclonal antibodies towards the MOG extracellular domain are available; one raised against the human recombinant protein (cat# 55158) and the other against the mouse recombinant protein (cat# 55150). These Protein A affinity purified antibodies recognized a 27kDa band.

SensoLyte® Anti-MOG IgG ELISA Assay Kits

The SensoLyte Anti-Human MOG (1-125) IgG Quantitation ELISA Kit, SensoLyteÒ Anti-Mouse MOG (1-125) and SensoLyteÒ Anti-Rat MOG (1-125) IgG ELISA assay kits are useful for determining the amount of anti-human MOG (1-125), anti-mouse MOG (1-125) and anti-rat MOG (1-125) antibodies, respectively. These kits, as well as the recombinant MOG (1-125) proteins are examples of innovative products from AnaSpec.


The SensoLyte® Anti-MOG (35-55) IgG Quantitative ELISA kits are optimized to detect anti-MOG (35-55) mouse/rat IgG and IgG subtypes. Using strips pre-coated with MOG (35-55) peptide and pre-blocked with BSA, the amount of anti-MOG IgG subtypes in serum or cerebrospinal fluid can be determined by ELISA and the absorbance read at 450 nm.

References:
1. Linares, D. et al. Protein Expression and Purif. 34, 249 (2004).
2. Bettadapura, J. et al. J. Neurochem. 70, 1593 (1998).
3. Oliver, AR. et al J. Immunol. 171, 462 (2003).
4. Von Budingen, H-C. et al. J. Clin. Immunol. 21, 155 (2001).
5. Lyons, J-A. et.al. Eur. J. Immunol. 29, 3432 (1999).
6. Von Budingen, H-C. et.al. Eur. J. Immunol. 34, 2072 (2003).


About AnaSpec

AnaSpec is a leading provider of integrated proteomics solutions to the world’s largest biotech, pharmaceutical, and academic research institutions. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and antibodies.

For more information visit www.anaspec.com

###
_________________
Ping Yang
Marketing Speialist
34801 Campus Drive
Fremont, CA 94555
1-800-452-5530 (Toll free)
1-510-791-9560 (Tel)
1-510-791-9572 (Fax)
ping@anaspec.com
www.anaspec.com
Back to top
View user's profile Send private message Send e-mail Visit poster's website
Display posts from previous:   
Post new topic   Reply to topic    Press Release Forum [pressreleaseforum.com] Forum Index -> Biotech Press Releases All times are GMT - 4 Hours
Page 1 of 1

 
Jump to:  
You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum
You cannot vote in polls in this forum

Submit Press Release (Free)Submit Press Release